Stewart Factor, DO

Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline ...

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Juha-Matti Savola , MD, PhD;

Nicholas Gross , MS;

Stewart Factor , DO;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

11/22/2019

Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia

BACKGROUND: Deutetrabenazine, a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved by the FDA for treatment of tardive dyskinesia (TD) in adults. Dopamine-receptor ant...

Maria Wieman , MPH;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Juha-Matti Savola , MD, PhD;

Mark Forrest Gordon , MD;

Stewart Factor , DO;

11/22/2019

Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels. Deutetrab...

Hubert Fernandez , MD;

Stewart Factor , DO;

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

William Ondo , MD;

Fredrick Jarskog , MD;

Scott Woods , MD;

Mark LeDoux , MD, PhD;

David Shprecher , DO, MS;

Karen Anderson , MD;

03/01/2019

Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study

Background: Deutetrabenazine was efficacious and safe in treating tardive dyskinesia (TD) in the 12-week ARM-TD and AIM-TD studies. Objective: To evaluate the long-term safety and tolerab...

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

William Ondo , MD;

Hubert Fernandez , MD;

Fredrick Jarskog , MD;

Scott Woods , MD;

Mark LeDoux , MD, PhD;

David Shprecher , DO, MS;

Stewart Factor , DO;

03/01/2019

Early Response With Valbenazine and Long-Term Symptom Reduction in Patients With Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study

Background: Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from ...

Khodayar Farahmand , PharmD;

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Stewart Factor , DO;

Leslie Lundt , MD;

Stanley Caroff , MD;

11/22/2019